Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly logo

Dust‑Mite Component Testing (Der p 1, Der p 2, Der p 23): How It Informs At‑Home Immunotherapy

Why dust‑mite “components” show up on test reports

Component‑resolved diagnostics (CRD) breaks an allergen (like house‑dust mite) into specific proteins called components. For dust mites, clinicians often reference Der p 1, Der p 2, and Der p 23 from Dermatophagoides pteronyssinus (and homologs from D. farinae). CRD can help confirm true dust‑mite sensitization versus cross‑reactivity and, in some cases, refine counseling alongside your history and environment.

  • What Wyndly tests by default: our at‑home blood test measures allergen‑specific IgE to common indoor/outdoor allergens, including dust mite species Dermatophagoides farinae and D. pteronyssinus, as listed on our Allergen List. We do not routinely order individual component IgE panels.

  • How we use outside results: if you already have a component panel (e.g., Der p 1/2/23) from another lab, our physicians will review it with your clinical history and environment to guide treatment. See our existing‑test review option on site.

  • Scope reminder: Wyndly treats environmental allergies (dust mites, pollens, pets, molds). We do not test for or treat food allergies; component panels for foods are out‑of‑scope for our care model. Learn more about our Immunotherapy approach.

Dust‑mite CRD in plain language

House‑dust mite (HDM) extracts contain many proteins. Component tests report IgE to individual proteins. Clinicians commonly discuss:

Component (example) Typical source Practical use in CRD How Wyndly interprets it (with history)
Group 1 (e.g., Der p 1) D. pteronyssinus Often associated with genuine HDM sensitization Supports HDM as a meaningful trigger when paired with species‑level IgE and symptoms
Group 2 (e.g., Der p 2) D. pteronyssinus Another major HDM protein used to confirm sensitization Similar to Group 1: strengthens the case for HDM‑directed therapy
Group 23 (e.g., Der p 23) D. pteronyssinus Additional major protein sometimes included on CRD panels Adds confidence that HDM is clinically relevant, but management still centers on exposure control + immunotherapy

Notes:

  • Component names differ by species (e.g., Der f 1/2 for D. farinae), but their clinical role is analogous.

  • A positive component does not replace your story (symptoms where you live/sleep, seasonality, indoor humidity) when deciding treatment.

When component results may change counseling

CRD is most helpful when:

  • Species‑level IgE is borderline but history strongly suggests dust‑mite triggers (CRD can add confidence to proceed with therapy and environmental control).

  • Multiple perennial allergens are positive and you need to prioritize what to address first at home (bedding, humidity, cleaning cadence). See Wyndly’s dust‑mite education for practical control steps: Dust mite overview and Prevention tips.

In most routine cases, species‑level IgE to D. farinae and/or D. pteronyssinus, plus a consistent history, is sufficient to start treatment; components rarely alter the choice of immunotherapy.

What this means for treatment with Wyndly

  • Root‑cause therapy: Wyndly uses doctor‑supervised sublingual immunotherapy (SLIT) drops/tablets to desensitize your immune system to dust mites and other environmental allergens. Clinical summaries and society guidance referenced on our Immunotherapy page show SLIT is an effective, safe alternative to allergy shots for long‑term relief.

  • Tablets vs drops: For dust mites specifically, FDA‑approved SLIT tablets exist; our physicians may recommend tablets or custom drops based on your profile. Either path is taken daily at home and monitored by our team. See our pollen/dust SLIT page for timelines and safety details.

  • Multi‑allergen care: If you’re also sensitized to pets, pollens, or molds, we routinely treat multiple environmental allergens together with SLIT drops; there’s no per‑allergen fee. Review your full panel on the Allergen List.

Typical expectations (from Wyndly resources):

  • Onset of benefit: many patients notice improvement between 4 weeks and 6 months, with durability after a multi‑year course. Details on timelines and safety are outlined on our Immunotherapy and FAQ pages.

Practical next steps

1) Confirm triggers: if you haven’t tested, start with our CLIA‑certified at‑home blood test that includes dust‑mite species—see the full Allergen List. 2) Optimize your environment: wash bedding ≥130°F weekly, encase pillows/mattress, and keep indoor humidity <50%. Guidance here: Prevent dust‑mite allergies. 3) Choose immunotherapy: meet a Wyndly physician to select SLIT tablets or drops for dust mites (and any other environmental allergens). Learn how SLIT works and what to expect on our Immunotherapy page.

Limitations and scope

  • CRD is an adjunct, not a standalone decision‑maker. Treatment decisions rely on history, examination, and standard IgE testing.

  • Wyndly does not treat food allergies; food component testing (e.g., storage vs PR‑10 proteins) is outside our care scope.

  • For U.S. patients ages 5+, environmental allergies only (pets, pollens, dust, molds), consistent with our program details.